Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression

Figures & data

Table 1 Clinical and pathological data

Age at diagnosis (median)		44 years
Smoking history	Yes	28.8% (n=17)
No	71.2% (n=42)
Histologic subtype	Squamous cell	86.4% (n=51)
Adenocarcinoma	13.6% (n=8)
PS	0	28.8% (n=17)
	1	62.7% (n=32)
	2	5.1% (n=3)
	3	3.4% (n=2)
4	–
CS (FIGO, 2009)	I	10.1% (n=6)
	II	30.5% (n=18)
	III	40.7% (n=24)
	IVA	13.6% (n=8)
IVB	5.1% (n=3)
Treatament	Surgery (frontline)	27.1% (n=16)
	CT-RT	64% (n=38)
	Brachytherapy	32.2% (n=19)
RT (exclusive)	16% (n=9)
Endpoint	Progression	47.5% (n=28)
	Death	33.9% (n=20)
Follow-up (median)	26.2 months

Abbreviations: PS, performance status; CS, clinical stage.

Figure 1 Flowchart of cohort recruitment.

Figure 2 Immunohistochemical staining of PD-L1 was considered positive if cell membrane staining was detected, and FoxP3 staining was considered positive if nuclear staining was detected. Black arrows point to staining detection areas. PD-L1-positive squamous cell cervical neoplasia (A); 400× magnification. PD-L1-positive peritumoral inflammatory infiltrate (B); 400× magnification. FoxP3-positive squamous cell cervical neoplasia (C); 200× magnification. FoxP3-positive peritumoral inflammatory infiltrate (D; 400× magnification).

Figure 3 Kaplan–Meier curves and log-rank test analysis of the overall survival of patients with cervical neoplasia based on PD-L1 expression.

Figure 4 Kaplan–Meier curves and log-rank test analysis of the progression-free survival of patients with cervical neoplasia based on PD-L1 expression.

Figure 5 Kaplan–Meier curves and log-rank test analysis of overall survival (left) and progression-free survival (right) of patients with cervical neoplasia based on quantification of peritumoral lymphocytic infiltration.